Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - ACORDA THERAPEUTICS INC | acor-ex322_11.htm |
| EX-32.1 - EX-32.1 - ACORDA THERAPEUTICS INC | acor-ex321_7.htm |
| EX-31.2 - EX-31.2 - ACORDA THERAPEUTICS INC | acor-ex312_9.htm |
| EX-31.1 - EX-31.1 - ACORDA THERAPEUTICS INC | acor-ex311_6.htm |
| EX-21 - EX-21 - ACORDA THERAPEUTICS INC | acor-ex21_8.htm |
| EX-10.31 - EX-10.31 - ACORDA THERAPEUTICS INC | acor-ex1031_94.htm |
| 10-K - 10-K - ACORDA THERAPEUTICS INC | acor-10k_20171231.htm |
Exhibit 23
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-3 No. 333-196803) |
|
|
(2) |
Registration Statements (Form S-8 Nos. 333-131846, 333-149726, 333-158085, 333-164626, 333-174785, 333-179906, 333-187091, 333-194375, 333-202525, 333-206346, 333-210813 and 333-212917.) |
of our reports dated March 1, 2018, with respect to the consolidated financial statements of Acorda Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Acorda Therapeutics, Inc. included in this Annual Report (Form 10-K) of Acorda Therapeutics, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Hartford, Connecticut
March 1, 2018